Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer

用源自前列腺特异性抗原的激动剂肽 PSA: 154-163 (155L) 进行疫苗接种可诱导对天然肽 PSA: 154-163 的 CD8 T 细胞反应，但无法诱导对表达 PSA 的肿瘤靶标的反应性：复发性前列腺癌患者的 2 期研究